Company intelligence / Profile preview
CicloMed LLC
Kansas City, Missouri, United Statesciclomed.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
CicloMed is developing Fosciclopirox (formerly Ciclopirox Prodrug/CPX-POM), which has completed a Phase 1 safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patients. A Phase 1B expansion cohort study is evaluating Fosciclopirox in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) patients. The drug is also part of a Phase 1B/2A study for relapsed or refractory AML.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
The University of Kansas Cancer CenterKU's Institute for Advancing Medical Innovation (IAMI)Sarah Cannon Research Institute
Beyond the preview
Go deeper on CicloMed LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CicloMed LLC.